Nordic Pharma Announces European Launch of Lacrifill® for Dry Eye Disease

Hoofddorp, Netherlands – 6th February 2026 – Nordic Group B.V., an international pharmaceutical company operating as Nordic Pharma, announced today the introduction of Lacrifill®, a novel therapy for dry eye, to the European market. Following CE mark approval in 2025, Lacrifill® is now available to healthcare professionals and patients across a range of European markets, marking a major step in the treatment of dry eye disease.

Lacrifill® is a cross-linked hyaluronic acid gel designed to temporarily block tear drainage by
physiologically occluding the canalicular system. By enhancing tear filmpreservation, Lacrifill® helpsmaintain natural lubricating tears on the patients’ ocular surface, offering an individualised approach to dry eye management. The in-office procedure provides a
full fill of the canalicular system and delivers long-lasting effects for up to six months.